

[Click here to access the guidelines/NICE algorithm](#)

**N&WICS - TA676 - Filgotinib with methotrexate - Severe rheumatoid arthritis**

Before providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and/or CSU for processing this funding request and validating subsequent invoices. Consent given: ☐

If there is more than one NICE-approved treatment available, a discussion between the responsible clinician and the patient has taken place about the advantages and disadvantages of the treatments available. This has taken into consideration therapeutic need and whether or not the patient is likely to adhere to treatment. The most appropriate, least expensive, will be chosen (taking into account administration costs, dosage and price per dose) unless an order of preference is stated in the TAs. ☐

<b>Patient NHS No:</b>	<b>Trust:</b>	<b>Practice Name:</b>
<b>Patient Hospital No:</b> <input type="text"/>	<b>Consultant Making Request:</b> <input type="text"/>	<b>Practice Postcode:</b>
<b>Patient's Initials and DoB:</b>		<b>Practice Code:</b>
<b>Notification Email Address:</b> <input type="text"/> (@NHS.net account ONLY)		<b>Contact name &amp; number:</b> <input type="text"/>
<b>Start date of requested treatment:</b> <input type="text"/>	<b>Provider:</b> <input type="checkbox"/> Private <input type="checkbox"/> NHS <b>Supplier:</b> <input type="checkbox"/> Homecare <input type="checkbox"/> Hospital	<b>Sub-Type:</b> <input type="text"/> N/A <input type="text"/> <input type="text"/> (if applicable)

By completing this form, you confirm that you intend to use the requested medicinal product described below as agreed in the local commissioning statement. Any requests which fall outside of this use will require an individual funding request (IFR).

For support regarding IFRs, please contact: [norfolkicd@nhs.net](mailto:norfolkicd@nhs.net)

For support regarding the criteria listed below, please contact: [norfolknontariff@nhs.net](mailto:norfolknontariff@nhs.net)

<b>Please indicate whether patient meets the following NICE criteria:</b>	<b>Please tick</b>
1. Filgotinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs), only if: <ul style="list-style-type: none"> <li>disease is moderate or severe (a disease activity score [DAS28] of 3.2 or more) and</li> <li>the company provides filgotinib according to the commercial arrangement.</li> </ul>	<input type="checkbox"/> Yes <input type="checkbox"/> No
2. Filgotinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if: <ul style="list-style-type: none"> <li>disease is severe (a DAS28 of more than 5.1) and</li> <li>they cannot have rituximab and</li> <li>the company provides filgotinib according to the commercial arrangement.</li> </ul>	<input type="checkbox"/> Yes <input type="checkbox"/> No
3. Filgotinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to rituximab and at least 1 biological DMARD, only if: <ul style="list-style-type: none"> <li>disease is severe (a DAS28 of more than 5.1) and</li> <li>the company provides filgotinib according to the commercial arrangement.</li> </ul>	<input type="checkbox"/> Yes <input type="checkbox"/> No
4. Filgotinib can be used as monotherapy when methotrexate is contraindicated or if people cannot tolerate it, when the criteria in sections 1.1, 1.2 or 1.3 are met.	<input type="checkbox"/> Yes <input type="checkbox"/> No
5. Choose the most appropriate treatment after discussing the advantages and disadvantages of the treatments available with the person having treatment. If more than 1 treatment is suitable, start treatment with the least expensive drug (taking into account administration costs, dose needed and product price per dose). This may vary from person to person because of differences in how the drugs are taken and treatment	<input type="checkbox"/> Yes <input type="checkbox"/> No

schedules.		
6. Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. If this initial response is not maintained, stop treatment.		<input type="checkbox"/> Yes <input type="checkbox"/> No
7. When using the DAS28, healthcare professionals should take into account any physical, psychological, sensory or learning disabilities, or communication difficulties that could affect the responses to the DAS28 and make any adjustments they consider appropriate.		<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>I confirm that the patient meets the criteria for treatment</b>		
Name of person completing: <input type="text"/>		Contact Details: <input type="text"/>
Designation of person completing: <input type="text"/>		Date: <input type="text"/>
Trust Authorising Pharmacist		
Name: <input type="text"/>		
Date: <input type="text"/>		